Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom's Shares Soar on Launch of Fetal Sex Determination Test

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Shares of Sequenom were up 14 percent in mid-afternoon trade on the Nasdaq after the firm announced earlier today the launch of its SensiGene Fetal (XY) test through its CLIA lab, the Sequenom Center for Molecular Medicine.

The new SensiGene test is a non-invasive assay that detects circulating cell-free fetal DNA in maternal blood. It interrogates male specific targets on the Y chromosome and runs on Sequenom's MassArray system.

Sequenom said that a validation study showed that the test had 97.9 percent sensitivity and 100 percent specificity.

The firm's shares were up $.63 at $5.15 in Tuesday afternoon trade on the Nasdaq.

Two weeks ago, Sequenom's shares spiked on the launch of its SensiGene Fetal RHD Genotyping test.

Sequenom's shares had not traded above $5 since late September 2009. At that time, the firm had announced the dismissal of its CEO and other top executives in the wake of an investigation into the mishandling of test data on its Down Syndrome test.

The Scan

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.

DNA Storage Method Taps Into Gene Editing Technology

With a dual-plasmid system informed by gene editing, researchers re-wrote DNA sequences in E. coli to store Charles Dickens prose over hundreds of generations, as they recount in Science Advances.

Researchers Model Microbiome Dynamics in Effort to Understand Chronic Human Conditions

Investigators demonstrate in PLOS Computational Biology a computational method for following microbiome dynamics in the absence of longitudinally collected samples.

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.